BiVictriX Therapeutics plc (AIM:BVX)
London · Delayed Price · Currency is GBP · Price in GBX 10.00
+1.50 (17.65%)
Inactive · Last trade price on Sep 10, 2024
BiVictriX Therapeutics Company Description
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom.
The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia.
The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021.
BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
BiVictriX Therapeutics plc
| Country | United Kingdom |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Tiffany Thorn |
Contact Details
Address: Mereside Macclesfield |
Stock Details
| Ticker Symbol | BVX |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BNXH3K91 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tiffany Thorn | Chief Executive Officer |
| Adrian Howd | Chief Financial Officer |